{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:29:17Z","timestamp":1788348557840,"version":"build-2803163510"},"reference-count":34,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2025,6,9]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To conduct a performance analysis of intra-arterial chemotherapy (IAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>Comprehensive data search in MEDLINE from inception until December 2023. Peer-reviewed, English-language, clinical studies (retrospective, prospective, trials, non-randomised) and case series. Two authors abstracted data independently using a standardised form. Study heterogeneity calculation and influence statistics with a leave-one-out analysis were carried out. Globe salvage rates (GSR) (overall, primary and secondary), per international classification of retinoblastoma groups and adjuvant intravitreal chemotherapy were carried out. Performance was assessed using learning curve, experience and study variable effects (site, size and year).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>416 identified studies met the selection criteria. 43 studies (3174 eyes) were included for random-effects meta-analysis. The statistical test for heterogeneity was significant (p value&lt;0.001). Overall GSR was 73% (95% CI 68 to 77%) and comparable when used as primary (69%, 95% CI 63 to 75%) or as secondary treatment (66%, 95% CI 58 to 74%). GSR was higher (66%, 95% CI 60 to 71%), for group D eyes than for group E eyes (49%, 95% CI 39 to 59%). There was insufficient evidence to conclude the modifying effect of adjuvant intravitreal chemotherapy. Analysis for learning curve effect revealed no improvement in GSR from a unique centre with time. Analysis for the experience effect was precluded due to lack of sufficient data. GSR was not impacted by the national income level of the study site (p value 0.07), study size (&lt;50 eyes vs &gt;=50 eyes, p value 0.449) or year (&lt;=2020 versus &gt;2020, p value &lt;0.0.075).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Improved selection criteria are needed to identify eyes suitable for IAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2025-327728","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T13:21:24Z","timestamp":1750425684000},"page":"1298-1305","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Intra-arterial chemotherapy for retinoblastoma: a performance analysis"],"prefix":"10.1136","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5923-769X","authenticated-orcid":false,"given":"Yehonatan","family":"Weinberger","sequence":"first","affiliation":[{"name":"Department of Ocular oncology, Cole eye institute, Cleveland Clinic, Cleveland, Ohio, USA"},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv-Yafo, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloni","family":"Kapoor","sequence":"additional","affiliation":[{"name":"UPMC Vision Institute, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C","family":"Zabor","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences & Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-0320","authenticated-orcid":false,"given":"Arun D","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Ocular oncology, Cole eye institute, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"2026012223102362000_109.11.1298.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2024.01.013"},{"key":"2026012223102362000_109.11.1298.2","doi-asserted-by":"crossref","unstructured":"Singh AD , Jia R , Fan X . Retinoblastoma: choosing treatment. In: Berry JL , Damato BE , Singh AD , eds. Clinical ophthalmic oncology: retinoblastoma. Cham: Springer Nature Switzerland, 2024: 145\u201350.","DOI":"10.1007\/978-3-031-77177-4_13"},{"key":"2026012223102362000_109.11.1298.3","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2019-014909"},{"key":"2026012223102362000_109.11.1298.4","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.1016\/S2214-109X(22)00250-9","article-title":"The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries","volume":"10","author":"Global Retinoblastoma Study","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2026012223102362000_109.11.1298.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.12.014"},{"key":"2026012223102362000_109.11.1298.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146582","article-title":"Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma","volume":"11","author":"Abramson","year":"2016","journal-title":"PLoS One"},{"key":"2026012223102362000_109.11.1298.7","doi-asserted-by":"publisher","DOI":"10.3109\/08820538.2014.959188"},{"key":"2026012223102362000_109.11.1298.8","unstructured":"Jenkins R , Lemire C , Altamirano-Lamarque F , et al . Complications of intra-arterial chemotherapy (iac) for retinoblastoma: an updated, comprehensive review. 2023. Available: https:\/\/wwwaaoorg\/education\/disease-review\/complications-of-intra-arterial-chemotherapy-iac-r"},{"key":"2026012223102362000_109.11.1298.9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.0244"},{"key":"2026012223102362000_109.11.1298.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4406-6","article-title":"Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Cancer"},{"key":"2026012223102362000_109.11.1298.11","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02610-z"},{"key":"2026012223102362000_109.11.1298.12","first-page":"1","article-title":"The Safety and Effectiveness of Melphalan-Based Intra-Arterial Chemotherapy for Retinoblastoma: An Updated Single-Arm Systematic Review and Meta-Analysis","volume":"2022","author":"Cao","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"2026012223102362000_109.11.1298.13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.17219\/acem\/166664","article-title":"A meta-analysis of the efficacy of intra-arterial chemotherapy for the management of retinoblastoma patients","volume":"33","author":"Yu","year":"2024","journal-title":"Adv Clin Exp Med"},{"key":"2026012223102362000_109.11.1298.14","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2007.057190"},{"key":"2026012223102362000_109.11.1298.15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.003981","article-title":"Surgeon Experience and Outcomes: An Age Old Question","volume":"10","author":"Waljee","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026012223102362000_109.11.1298.16","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/applbiosci2040042","article-title":"Statistical Analysis of Ceiling and Floor Effects in Medical Trials","volume":"2","author":"Arslan","year":"2023","journal-title":"Applied Biosciences"},{"key":"2026012223102362000_109.11.1298.17","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/00004872-199609002-00004","article-title":"Advantages and disadvantages of the meta-analysis approach","volume":"14","author":"Fagard","year":"1996","journal-title":"J Hypertens Suppl"},{"key":"2026012223102362000_109.11.1298.18","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2026012223102362000_109.11.1298.19","unstructured":"World bank country and lending groups, the world bank. 2025 Available: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"key":"2026012223102362000_109.11.1298.20","unstructured":"R Core Team (2024) . R: a language and environment for statistical computing. R Foundation for Statistical Computing V, Austria; 2024. Available: https:\/\/www.R-project.org"},{"key":"2026012223102362000_109.11.1298.21","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"2026012223102362000_109.11.1298.22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.2243"},{"key":"2026012223102362000_109.11.1298.23","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.150"},{"key":"2026012223102362000_109.11.1298.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-015-3202-0"},{"key":"2026012223102362000_109.11.1298.25","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.158076"},{"key":"2026012223102362000_109.11.1298.26","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_843_16"},{"key":"2026012223102362000_109.11.1298.27","doi-asserted-by":"publisher","DOI":"10.1080\/13816810.2016.1244695"},{"key":"2026012223102362000_109.11.1298.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.12.030"},{"key":"2026012223102362000_109.11.1298.29","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2013.56.6.254"},{"key":"2026012223102362000_109.11.1298.30","doi-asserted-by":"crossref","DOI":"10.1136\/neurintsurg-2021-018409","article-title":"Correspondence on \u201cIntra-arterial chemotherapy for retinoblastoma: an updated systematic review and meta-analysis\u201d by Ravindran et al","volume":"14","author":"Promelle","year":"2022","journal-title":"J Neurointerv Surg"},{"key":"2026012223102362000_109.11.1298.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2024.05.001"},{"key":"2026012223102362000_109.11.1298.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.12.012"},{"key":"2026012223102362000_109.11.1298.33","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30071","article-title":"Ocular survival after intra-arterial chemotherapy for retinoblastoma improves with accrual of experience and programmatic evolution","volume":"70","author":"Marasligiller","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"2026012223102362000_109.11.1298.34","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319118"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2025-327728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:10:44Z","timestamp":1769152244000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2025-327728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,10,23]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bjo-2025-327728"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2025-327728","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}